AN 1006
Latest Information Update: 19 Oct 1994
At a glance
- Originator Meiji Seika Kaisha
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Oct 1994 Discontinued-Preclinical for Cancer in Japan (Unknown route)